×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ONCY – oncolytics biotech inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ONCY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/5
09:54 am
oncy
$207B Market Shift: The Race for Fast Track Approval in Oncology [Globe and Mail, The (Toronto, Canada)]
Low
Report
$207B Market Shift: The Race for Fast Track Approval in Oncology [Globe and Mail, The (Toronto, Canada)]
2/5
09:26 am
oncy
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Medium
Report
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
2/4
08:50 am
oncy
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
High
Report
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
1/30
10:50 am
oncy
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium [Globe and Mail, The (Toronto, Canada)]
Low
Report
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium [Globe and Mail, The (Toronto, Canada)]
1/30
10:33 am
oncy
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors [Globe and Mail, The (Toronto, Canada)]
Low
Report
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors [Globe and Mail, The (Toronto, Canada)]
1/30
10:19 am
oncy
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
Low
Report
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
1/28
09:45 am
oncy
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment [Globe and Mail, The (Toronto, Canada)]
Low
Report
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment [Globe and Mail, The (Toronto, Canada)]
1/27
11:11 am
oncy
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks [Globe and Mail, The (Toronto, Canada)]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
05:28 pm
oncy
oncolytics biotech inc. - common shares
MISS
Report
-3.6%
oncolytics biotech inc. - common shares
8/8/2025
09:05 am
oncy
oncolytics biotech inc. - common shares
BEAT
Report
-7.7%
oncolytics biotech inc. - common shares
5/14/2025
04:01 pm
oncy
oncolytics biotech inc. - common shares
BEAT
Report
-3.4%
oncolytics biotech inc. - common shares
3/7/2025
07:00 am
oncy
oncolytics biotech inc. - common shares
MISS
Report
-10.5%
oncolytics biotech inc. - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/4
12:05 pm
oncy
Form 8-K ONCOLYTICS BIOTECH INC For: Feb 04
Medium
Report
Form 8-K ONCOLYTICS BIOTECH INC For: Feb 04
1/20
04:30 pm
oncy
Form 4 ONCOLYTICS BIOTECH INC For: Jan 16 Filed by: Seizinger Bernd R.
High
Report
Form 4 ONCOLYTICS BIOTECH INC For: Jan 16 Filed by: Seizinger Bernd R.
1/15
04:22 pm
oncy
Form 8-K ONCOLYTICS BIOTECH INC For: Jan 15
Medium
Report
Form 8-K ONCOLYTICS BIOTECH INC For: Jan 15
1/15
06:02 am
oncy
Form 8-K ONCOLYTICS BIOTECH INC For: Jan 14
Medium
Report
Form 8-K ONCOLYTICS BIOTECH INC For: Jan 14
1/12
04:06 pm
oncy
Form 8-K ONCOLYTICS BIOTECH INC For: Jan 08
Low
Report
Form 8-K ONCOLYTICS BIOTECH INC For: Jan 08
1/9
09:18 am
oncy
Form 425 ONCOLYTICS BIOTECH INC Filed by: ONCOLYTICS BIOTECH INC
Low
Report
Form 425 ONCOLYTICS BIOTECH INC Filed by: ONCOLYTICS BIOTECH INC
1/7
09:04 am
oncy
Form 6-K ONCOLYTICS BIOTECH INC For: Jan 07
Low
Report
Form 6-K ONCOLYTICS BIOTECH INC For: Jan 07
1/2
04:31 pm
oncy
Form 3 ONCOLYTICS BIOTECH INC For: Jan 01 Filed by: Hagerman Allison
Low
Report
Form 3 ONCOLYTICS BIOTECH INC For: Jan 01 Filed by: Hagerman Allison
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
33.3%
1/3 Form SUPPL ONCOLYTICS BIOTECH INC 17.3%
10/30 Breast Cancer Awareness Month Arrives With New Teamwork From Biotech Developers on the Way 17.2%
8/16 Form SUPPL ONCOLYTICS BIOTECH INC 15.6%
11/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 14.5%
1/2 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its price target raised by analysts at Roth Capital from $6.80 to $9.00. They now have a "buy" rating on the stock. 13.8%
10/15 Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors 10.6%
3/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $300.00 price target on the stock. 10.0%
3/4 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 8.7%
11/12 Form 6-K ONCOLYTICS BIOTECH INC For: Nov 12 8.1%
1/3 Form SUPPL ONCOLYTICS BIOTECH INC 17.3%
10/30 Breast Cancer Awareness Month Arrives With New Teamwork From Biotech Developers on the Way 17.2%
8/16 Form SUPPL ONCOLYTICS BIOTECH INC 15.6%
11/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 14.5%
1/2 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its price target raised by analysts at Roth Capital from $6.80 to $9.00. They now have a "buy" rating on the stock. 13.8%
10/15 Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors 10.6%
3/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $300.00 price target on the stock. 10.0%
3/4 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 8.7%
11/12 Form 6-K ONCOLYTICS BIOTECH INC For: Nov 12 8.1%
TOP News Decliners
8/13
Oncolytics Biotech(R) Announces Public Offering of Common Shares and Warrants
-34.0%
11/5 Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights -21.9%
1/14 Form 6-K ONCOLYTICS BIOTECH INC For: Jan 13 -20.5%
1/1 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -18.4%
3/5 Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights -17.3%
1/13 Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma -16.0%
6/5 Oncolytics Biotech's (ONCY) Co-Development Agreement with Pfizer and Merck KGaA Call (Transcript) [Seeking Alpha] -14.1%
12/6 Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement -12.3%
3/9 Form SUPPL ONCOLYTICS BIOTECH INC -11.1%
6/5 Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer -10.0%
11/5 Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights -21.9%
1/14 Form 6-K ONCOLYTICS BIOTECH INC For: Jan 13 -20.5%
1/1 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -18.4%
3/5 Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights -17.3%
1/13 Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma -16.0%
6/5 Oncolytics Biotech's (ONCY) Co-Development Agreement with Pfizer and Merck KGaA Call (Transcript) [Seeking Alpha] -14.1%
12/6 Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement -12.3%
3/9 Form SUPPL ONCOLYTICS BIOTECH INC -11.1%
6/5 Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer -10.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: